Photopheresis in solid organ transplant rejection
β Scribed by Marisa B. Marques; Hande H. Tuncer
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 90 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0733-2459
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Photopheresis has become a key component in the therapeutic armamentarium of cutaneous Tβcell lymphoma, graftβversusβhost disease following stem cell transplant, and allograft rejection of solid organs such as heart. Although it is considered a new treatment modality in its present form, the field of phototherapy dates back thousands of years. In this review, the reader will learn more about the history of photopheresis and how it became a therapeutic alternative for patients with solid organ transplants. An extensive literature search will highlight the evidenceβbased benefits of photopheresis (or lack thereof). A discussion of the mechanism of action of photopheresis and the technical aspects of the procedure will also be covered. Since photopheresis may be the best tolerated form of immunomodulation, current promising, albeit preliminary data on its efficacy warrant further investigation and understanding. J. Clin. Apheresis 21:72β77, 2006. Β© 2006 WileyβLiss, Inc.
π SIMILAR VOLUMES
## Abstract Photopheresis has been used in the management of rejection of heart and/or lung transplants. Although its mechanism of action remains unknown, irradiated Tβhelper cellβinduced immunosuppression is the main theory. Since transplant recipients are often lymphopenic and lymphocytes are the
Post-transplant hemolytic uremic syndrome characterized by microangiopathic hemolysis, thrombocytopenia, and renal failure is an infrequent but potentially serious complication in organ transplant recipients. Hemolytic uremic syndrome developed in 2% (2/100) of our consecutive liver transplants. We